Adaptive Biotechnologies Corporation (ADPT) Bundle
Understanding Adaptive Biotechnologies Corporation (ADPT) Revenue Streams
Understanding Adaptive Biotechnologies Corporation’s Revenue Streams
Adaptive Biotechnologies Corporation operates primarily in two segments: Minimal Residual Disease (MRD) and Immune Medicine. The revenue breakdown for the nine months ended September 30, 2024, is as follows:
| Segment | Revenue (in thousands) | Year-over-Year Change ($) | Year-over-Year Change (%) |
|---|---|---|---|
| MRD Revenue | $105,380 | $33,403 | 46% |
| Immune Medicine Revenue | $26,118 | $(26,397) | (50%) |
| Total Revenue | $131,498 | $7,006 | 6% |
For the three months ended September 30, 2024, the revenue breakdown is:
| Segment | Revenue (in thousands) | Year-over-Year Change ($) | Year-over-Year Change (%) |
|---|---|---|---|
| MRD Revenue | $37,470 | $12,802 | 52% |
| Immune Medicine Revenue | $8,965 | $(4,286) | (32%) |
| Total Revenue | $46,435 | $8,516 | 22% |
The MRD segment experienced significant growth, primarily driven by service revenue from clonoSEQ, which had a 30% increase in test volume, totaling 19,600 tests delivered in the three months ended September 30, 2024, compared to 15,072 tests during the same period in 2023.
On the other hand, the Immune Medicine segment faced a decline in revenue, largely due to a $24.7 million decrease in revenue from the Genentech Agreement, which significantly impacted collaboration revenue.
The year-over-year revenue growth rate reflects the following trends:
- MRD Revenue Growth: Increased from $71,977 thousand in 2023 to $105,380 thousand in 2024, marking a 46% rise.
- Immune Medicine Revenue Decline: Decreased from $52,515 thousand in 2023 to $26,118 thousand in 2024, indicating a 50% drop.
Overall, the total revenue for the nine months ended September 30, 2024, was $131,498 thousand, a 6% increase compared to $124,492 thousand in the same period of 2023.
Adaptive Biotechnologies’ varied revenue streams illustrate the contrasting performance of its segments, with MRD showing robust growth while Immune Medicine faced challenges, impacting the overall revenue trajectory for the company.
A Deep Dive into Adaptive Biotechnologies Corporation (ADPT) Profitability
A Deep Dive into Adaptive Biotechnologies Corporation's Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the gross profit margin was approximately 59%, compared to 55% for the same period in 2023. The gross profit for the nine months ended September 30, 2024, was $77,463 thousand, while for the nine months ended September 30, 2023, it was $68,555 thousand.
Operating Profit Margin: The operating loss for the nine months ended September 30, 2024, was $128,712 thousand, resulting in an operating margin of -98%. In comparison, for the nine months ended September 30, 2023, the operating loss was $139,908 thousand, yielding an operating margin of -112%.
Net Profit Margin: The net loss attributable to the company for the nine months ended September 30, 2024, was $125,800 thousand, translating to a net profit margin of -96%. For the nine months ended September 30, 2023, the net loss was $155,809 thousand, also reflecting a net profit margin of -125%.
Trends in Profitability Over Time
The profitability metrics show a gradual improvement in gross profit margins over the past year. The increase from 55% to 59% indicates better cost control in revenue generation. However, both operating and net margins remain negative, pointing to ongoing challenges in managing operational expenses.
Comparison of Profitability Ratios with Industry Averages
The industry average gross profit margin for biotechnology firms is approximately 70%. The operating margin for the sector averages around -50%, while the net profit margin typically hovers around -30%. In contrast, the company’s performance highlights significant room for improvement, particularly in operational efficiency.
Analysis of Operational Efficiency
Operational efficiency metrics indicate a need for enhanced cost management. The cost of revenue for the nine months ended September 30, 2024, was $54,035 thousand, showing a slight decrease from $55,937 thousand in the prior year. This reflects a 3% reduction in costs, although the overall operating expenses remain high relative to revenue.
| Metric | 2024 (9 Months) | 2023 (9 Months) | Change (%) |
|---|---|---|---|
| Gross Profit Margin | 59% | 55% | +4% |
| Operating Loss | $128,712K | $139,908K | -8.6% |
| Net Loss | $125,800K | $155,809K | -19.3% |
| Cost of Revenue | $54,035K | $55,937K | -3% |
The analysis indicates that while gross profit margins are improving, operational adjustments are necessary to enhance overall profitability. The persistent net and operating losses emphasize the importance of strategic cost management initiatives to align with industry benchmarks.
Debt vs. Equity: How Adaptive Biotechnologies Corporation (ADPT) Finances Its Growth
Debt vs. Equity: How Adaptive Biotechnologies Corporation Finances Its Growth
As of September 30, 2024, Adaptive Biotechnologies Corporation reported long-term debt totaling $130.7 million. This figure includes a revenue interest liability of $132.7 million, reflecting the company's ongoing obligations under its Purchase Agreement with OrbiMed Royalty & Credit Opportunities IV, LP.
Short-term debt is relatively minimal, with current liabilities consisting of $10.0 million in operating lease liabilities and other short-term obligations. The company's total liabilities amount to $174.7 million, indicating a significant reliance on debt financing relative to its equity base.
The debt-to-equity ratio for Adaptive Biotechnologies Corporation stands at 0.60 as of September 30, 2024. This is calculated from total liabilities of $174.7 million and total equity of $290.6 million. In comparison, the biotechnology industry average debt-to-equity ratio is approximately 0.75, suggesting that the company is slightly less leveraged than its peers.
Recent debt activity includes the initial cash proceeds under the Purchase Agreement, which totaled $125.0 million. The company has the potential to receive an additional $125.0 million in subsequent installments, contingent upon meeting specific funding conditions. The effective interest rate on this debt is reported at 8.8%.
In terms of credit ratings, the company has not publicly disclosed a specific credit rating, but its financial health indicators suggest a cautious approach to debt. The balance between debt financing and equity funding is evident as the company has primarily funded operations through the sale of convertible preferred stock and common stock. This strategy allows the company to maintain a relatively lower level of debt while still accessing capital for growth initiatives.
| Debt Type | Amount (in millions) |
|---|---|
| Long-term Debt | $130.7 |
| Short-term Debt | $10.0 |
| Total Liabilities | $174.7 |
| Total Equity | $290.6 |
| Debt-to-Equity Ratio | 0.60 |
| Average Industry Debt-to-Equity Ratio | 0.75 |
| Purchase Agreement Proceeds | $125.0 |
| Potential Additional Proceeds | $125.0 |
| Effective Interest Rate | 8.8% |
Overall, Adaptive Biotechnologies Corporation's financing strategy reflects a balanced approach towards leveraging debt while maintaining a solid equity base, positioning the company for sustained growth amid its ongoing operational and developmental activities.
Assessing Adaptive Biotechnologies Corporation (ADPT) Liquidity
Assessing Adaptive Biotechnologies Corporation's Liquidity
Current Ratio: As of September 30, 2024, the current assets totaled $267.2 million, while current liabilities stood at $99.7 million, resulting in a current ratio of approximately 2.68.
Quick Ratio: The quick assets, which exclude inventory, were $265.5 million against current liabilities of $99.7 million, yielding a quick ratio of 2.67.
Analysis of Working Capital Trends
Working capital is calculated as current assets minus current liabilities. As of September 30, 2024, working capital was $167.5 million, indicating a strong liquidity position compared to the previous year, where it was $139.3 million.
| Period | Current Assets (in millions) | Current Liabilities (in millions) | Working Capital (in millions) |
|---|---|---|---|
| September 30, 2024 | $267.2 | $99.7 | $167.5 |
| September 30, 2023 | $240.5 | $101.2 | $139.3 |
Cash Flow Statements Overview
During the nine months ended September 30, 2024, the cash flow from operating activities was a net outflow of $82.7 million, compared to an outflow of $129.4 million for the same period in 2023. This reflects improvements in cash utilization despite ongoing losses.
Investing activities generated cash inflows of $55.7 million in 2024, primarily from maturities of marketable securities totaling $258.7 million, offset by purchases of marketable securities of $199.5 million.
Financing activities provided minimal cash inflows of $0.1 million in 2024, primarily from stock option exercises, compared to $2.2 million in 2023.
| Cash Flow Activity | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Operating Cash Flow | $(82.7) | $(129.4) |
| Investing Cash Flow | $55.7 | $126.4 |
| Financing Cash Flow | $0.1 | $2.2 |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company reported cash, cash equivalents, and marketable securities of $267.2 million, which is projected to cover operational needs for at least the next 12 months. The accumulated deficit was $1.3 billion as of the same date, indicating significant historical losses.
Future liquidity may require additional capital raises or installment requests under the existing Purchase Agreement, which allows for up to $125.0 million in additional funding, contingent on specific conditions being met.
Is Adaptive Biotechnologies Corporation (ADPT) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis of the company involves key financial ratios, stock performance, and analyst opinions that provide insights into whether the company is overvalued or undervalued.
Price-to-Earnings (P/E) Ratio
The P/E ratio as of the latest reporting period stands at — (data not available for current P/E ratio).
Price-to-Book (P/B) Ratio
The P/B ratio is currently — (data not available for current P/B ratio).
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is reported at — (data not available for current EV/EBITDA ratio).
Stock Price Trends
Over the past 12 months, the stock price has exhibited the following trends:
- 12 Months Ago: $— (price not available)
- Current Price: $— (price not available)
- Highest Price During Period: $— (price not available)
- Lowest Price During Period: $— (price not available)
Dividend Yield and Payout Ratios
The company does not currently offer a dividend, resulting in a dividend yield of 0%.
Analyst Consensus
The consensus among analysts is as follows:
- Buy: — analysts
- Hold: — analysts
- Sell: — analysts
Financial Summary Table
| Metric | Value |
|---|---|
| P/E Ratio | — |
| P/B Ratio | — |
| EV/EBITDA Ratio | — |
| Current Stock Price | — |
| 12-Month High | — |
| 12-Month Low | — |
| Dividend Yield | 0% |
| Analyst Consensus (Buy/Hold/Sell) | — / — / — |
Overall, the valuation metrics suggest a need for further analysis to determine the intrinsic value of the company relative to its current stock price.
Key Risks Facing Adaptive Biotechnologies Corporation (ADPT)
Key Risks Facing Adaptive Biotechnologies Corporation
The financial health of Adaptive Biotechnologies Corporation is influenced by various internal and external risks that can significantly impact its operations and overall market performance.
Industry Competition
Competition in the biotechnology sector is intense, with numerous companies vying for market share. As of September 30, 2024, the company reported a revenue of $131.5 million, a modest increase from $124.5 million in the same period the previous year. However, competition from established players and new entrants can lead to pricing pressures and reduced market share.
Regulatory Changes
Adaptive Biotechnologies operates in a heavily regulated environment. Changes in regulations can alter the landscape of product development and approval. The company experienced $7.2 million in impairment of long-lived assets in 2024 due to regulatory and operational restructuring efforts. Compliance with evolving regulations may increase operational costs and impact timelines for product launches.
Market Conditions
Fluctuations in market conditions can adversely affect revenue streams. The company's net loss was $125.8 million for the nine months ended September 30, 2024, compared to $155.8 million in the same period in 2023. Economic downturns can lead to reduced spending in healthcare and biotechnology sectors, impacting sales and profitability.
Operational Risks
Operational challenges, including supply chain disruptions and labor shortages, can hinder production and service delivery. The company reported a $1.9 million decrease in cost of revenue for the nine months ended September 30, 2024, with total cost of revenue at $54.0 million. Such fluctuations can affect margins and operational efficiency.
Financial Risks
Financial stability is a significant concern, particularly with an accumulated deficit of $1.3 billion as of September 30, 2024. The company has incurred losses since inception, raising concerns about its ability to sustain operations without additional funding. The $267.2 million in cash, cash equivalents, and marketable securities as of the same date indicates a need for prudent cash management.
Strategic Risks
Strategic decisions, such as partnerships and acquisitions, carry inherent risks. The company entered a revenue interest purchase agreement in September 2022, which could lead to further obligations and financial liabilities. Analyzing the success of such strategies is crucial for long-term sustainability.
Mitigation Strategies
To address these risks, the company is focusing on restructuring efforts that have already resulted in $9.1 million in recognized costs. This includes workforce reductions and asset impairment as part of a strategy to streamline operations and improve financial health. Monitoring market trends and regulatory developments will also be essential in adapting to changes swiftly.
| Risk Category | Description | Recent Impact |
|---|---|---|
| Industry Competition | Intense competition affecting market share and pricing | Revenue increased to $131.5 million |
| Regulatory Changes | Changes in regulations affecting product approval and costs | $7.2 million impairment of assets due to restructuring |
| Market Conditions | Economic fluctuations impacting spending | Net loss of $125.8 million for nine months ended September 30, 2024 |
| Operational Risks | Supply chain disruptions and labor shortages | Cost of revenue at $54.0 million |
| Financial Risks | Accumulated deficit and ongoing losses | Accumulated deficit of $1.3 billion |
| Strategic Risks | Risks associated with partnerships and acquisitions | Revenue interest agreement impacting future obligations |
Future Growth Prospects for Adaptive Biotechnologies Corporation (ADPT)
Future Growth Prospects for Adaptive Biotechnologies Corporation
Analysis of Key Growth Drivers
Adaptive Biotechnologies Corporation is strategically positioned to capitalize on several key growth drivers. These include:
- Product Innovations: The company continues to enhance its proprietary technologies, particularly in T cell receptor (TCR) and B cell receptor (BCR) sequencing. This innovation is expected to bolster their offerings in diagnostics and therapeutics.
- Market Expansions: There is a significant opportunity to expand into international markets, particularly in Europe and Asia, where demand for advanced immunosequencing technologies is growing.
- Acquisitions: The company is exploring strategic acquisitions to enhance its capabilities and market reach, particularly in the areas of drug discovery and therapeutics.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, the company reported total revenue of $131.5 million, up from $124.5 million in the same period of 2023, indicating a growth of 6%. The breakdown of revenue is as follows:
| Segment | 2024 Revenue (in thousands) | 2023 Revenue (in thousands) | Change ($) | Change (%) |
|---|---|---|---|---|
| MRD (Minimal Residual Disease) | $105,380 | $71,977 | $33,403 | 46% |
| Immune Medicine | $26,118 | $52,515 | ($26,397) | (50%) |
| Total | $131,498 | $124,492 | $7,006 | 6% |
Strategic Initiatives or Partnerships
The strategic partnership with Microsoft Corporation is noteworthy. This collaboration aims to develop the TCR-Antigen Map, which is expected to enhance the company's capabilities in identifying and validating disease signatures. Additionally, the ongoing collaboration with Genentech is projected to yield milestone payments, contributing to revenue growth.
Competitive Advantages
Adaptive Biotechnologies holds several competitive advantages that position it for future growth:
- Proprietary Technology: The company’s advanced sequencing technology provides a unique edge in the diagnostics market.
- Strong Market Position: With a significant share in the MRD testing market, the company benefits from established relationships with biopharmaceutical and academic customers.
- Financial Resilience: As of September 30, 2024, the company reported cash, cash equivalents, and marketable securities totaling $267.2 million, providing a solid foundation for future investments and growth initiatives.
Adaptive Biotechnologies Corporation (ADPT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Adaptive Biotechnologies Corporation (ADPT) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Adaptive Biotechnologies Corporation (ADPT)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Adaptive Biotechnologies Corporation (ADPT)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.